ABNCoV2  
COVID-19 vaccine

 

AdaptVac, as part of the EU H2020 funded PREVENT-nCoV consortium, is focused on developing a SARS-CoV-2 (COVID-19) vaccine using our capsid Virus-Like Particle (VLP) display technology.

The vaccine, ABNCoV2, has been exclusively licensed to Bavarian Nordic. Phase II study with 210 persons has been completed successfully, and DKK 800M has been committed by the Danish Ministry of Health to support the on-going PhIII trial.

ES2B-C001 
HER2+ Breast cancer vaccine

ES2B-C001, licensed to ExpreS2ion Biotechnologies, is currently in GMP manufacture, with plans to enter the clinic early 2024

In December 2021 and January 2022, positive preclinical proof-of-concept results were announced. In these studies, ES2B-C001 demonstrated a strong tumor-growth inhibiting effect in a mouse model and human cancer cells (December 2021), as well as in HER2-transgenic preventive and therapeutic tumor mice models (January 2022).Further excellent preclinical results were announced in May 2022, based on a new study in which HER2-transgenic mice were injected with HER2-positive tumors followed by vaccination every two weeks one week after challenge. All control mice had lung nodules, whereas all mice vaccinated with ES2B-C001 formulated in an adjuvant were metastasis-free. Furthermore, 73% of mice vaccinated with ES2B-C001 without adjuvant were metastasis-free, the remaining had only 1-2 lung nodules.

Pipeline Sept 2022.png

PIPELINE